-
Sino Biopharmaceutical’s Tulobuterol Patch Gains NMPA Approval
•
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its subsidiary Beijing Tide Pharmaceutical Co., Ltd has received marketing approval from the National Medical Products Administration (NMPA) for its tulobuterol patch. This marks the first approval of its kind domestically in China for a transdermal patch designed to relieve respiratory distress…
-
Regeneron’s Q4 Financials Show 10% Revenue Growth, Driven by Eylea and Libtayo
•
US-based biopharmaceutical company Regeneron (NASDAQ: REGN) released its Q4 2024 financial report, showing revenues up 10% year-on-year (YOY) to USD 3.79 billion. For the full year, sales grew by 8% to USD 14.2 billion. The results highlight the continued strength of Regeneron’s portfolio, particularly its top-selling products. Top Performers in…
-
AstraZeneca’s 2024 Financials Beat Expectations with 21% Revenue Growth
•
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) reported total revenues of USD 54.07 billion in its 2024 financial report, marking a 21% year-on-year (YOY) increase in constant exchange rate terms. Product sales reached USD 50.98 billion, up 19% YOY, with Q4 product sales climbing 19% to USD 13.36 billion. The…
-
Eli Lilly’s Q4 Sales Soar 45% to $13.53B on Strength of GLP-1 Drugs
•
Eli Lilly & Co. (NYSE: LLY) reported a robust finish to 2024, with Q4 revenues climbing 45% year-on-year (YOY) to reach USD 13.53 billion. The surge was primarily fueled by its GLP-1 drugs Mounjaro and Zepbound (tirzepatide). Excluding these incretin-focused drugs, Lilly’s overall portfolio still expanded by 20% YOY. For…
-
GSK Reports 7% Full-Year Sales Growth in 2024, Driven by Specialty Medicines
•
UK-based pharmaceutical giant GSK plc (NYSE: GSK) released its Q4 and full-year 2024 financial results, reporting a 7% year-on-year (YOY) growth in sales over the 12 months to GBP 31.38 billion (USD 40.1 billion). Excluding the impact of COVID-related products, the firm’s sales increased by 8% to GBP 31.36 billion.…
-
MSD Reports Strong Global Sales Growth in 2024, Despite China Challenges
•
US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) released its Q4 2024 financial report, highlighting strong global revenue growth. Global revenues reached USD 15.6 billion in Q4, up 9% year-on-year (YOY) excluding currency impacts. Over the full year, revenues increased 10% to USD 64.17 billion. The growth was driven…
-
Amgen Reports Strong Q4 and Full-Year 2024 Sales Growth
•
Amgen (NASDAQ: AMGN) released its Q4 2024 financial results this week, reporting USD 33.42 billion in annual sales after a robust 19% year-on-year (YOY) increase. Sales during Q4 reached USD 9.09 billion, up 11% YOY. The strong performance was driven by growth across key product lines and the impact of…
-
Novo Nordisk Reports Soaring Global Sales in 2024, Driven by Diabetes and Obesity Care
•
Denmark’s Novo Nordisk (CPH: NOVO-B) reported this week that its global sales during 2024 reached DKK 290.403 billion (USD 42.1 billion), marking a 26% year-on-year (YOY) increase at constant exchange rates (CER). The strong performance was driven by growth across all business sectors, with notable increases in GLP-1 diabetes, Insulin,…
-
Astellas Pharma Submits NDA for Avacincaptad Pegol in Japan for Geographic Atrophy
•
Japan-based major Astellas Pharma (TYO: 4503) announced that it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) seeking conditional approval for its avacincaptad pegol intravitreal solution (ACP). The drug is a synthetic aptamer that inhibits the complement C5 protein and is intended…
-
Roche’s Susvimo Approved by FDA for Diabetic Macular Edema
•
Swiss pharmaceutical giant Roche (SWX: ROG) announced that it has received approval from the US Food and Drug Administration (FDA) for another indication of its Susvimo (ranibizumab) 100 mg/mL, this time to treat diabetic macular edema (DME). With this approval, Susvimo becomes the first and only FDA-approved treatment shown to…
-
FDA Approves Enhertu for HER2-Low and HER2-UltraLow Breast Cancer
•
The US Food and Drug Administration (FDA) has approved Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody drug conjugate (ADC) co-developed by AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568), for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow…
-
Immunophage Partners with GoBroad Cancer Hospital for IPG1094 Phase II Study
•
Nanjing-headquartered Immunophage Biotech Co., Ltd., a targeted therapy developer with operations in China, Australia, and the US, has announced a comprehensive partnership with Shanghai GoBroad Cancer Hospital and China Pharmaceutical University. The collaboration, which follows their initial alliance in December of last year regarding IPG7236, is focused on the Phase…
-
Betta Pharmaceuticals Gains NMPA Approval for BPI-452080 Clinical Study
•
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study assessing its BPI-452080 in von Hippel-Lindau (VHL) syndrome-related tumors and solid tumors. This marks a significant step forward in the development of new treatments for…
-
Haisco’s HSK39004 Gains NMPA Approval for COPD Clinical Trials
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its HSK39004. The targeted small molecule inhibitor is now cleared to be assessed in clinical trials for chronic obstructive pulmonary disease (COPD), marking a significant step…
-
Sino Medical Sciences’ NC Rockstar Catheter Gains MDA Approval in Malaysia
•
China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received marketing approval from the Medical Device Authority (MDA) of Malaysia for its NC Rockstar non-compliant coronary artery balloon dilation catheter. The device is designed for balloon catheter dilation of autologous coronary artery or bypass stenosis to improve…
-
Henan Lingrui to Acquire Yingu Pharma for RMB 704 Million
•
China’s Henan Lingrui Pharmaceutical Co., Ltd. (SHA: 600285) announced plans to acquire a 90% ownership stake in Yingu Pharmaceutical Co., Ltd. for a consideration of RMB 704 million (USD 97 million). The deal underscores Lingrui’s strategic expansion in the pharmaceutical sector, targeting Yingu’s innovative product portfolio. Yingu Pharma’s Innovative Nasal…
-
Junshi Biosciences Receives NMPA Approval for JS213 Clinical Trials
•
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received clinical approval from the National Medical Products Administration (NMPA) for its JS213 sterile powder for injection. The drug is intended for use in combination with other anti-tumor drugs or as a standalone treatment for advanced…
-
Beijing Biostar’s Utidelone Gains FDA Approval for Global Phase II/III Study
•
China’s Beijing Biostar Technologies Ltd (HKG: 2563) announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a global multi-center Phase II/III regulatory study, dubbed BG02-2404. The study will evaluate utidelone in combination with capecitabine and oxaliplatin as a first-line treatment for PD-L1 negative…
-
ClouDr Group Integrates DeepSeeker R1 into CloudrBrain to Boost Chronic Disease Management
•
China-based ClouDr Group Limited (HKG: 9955) announced the integration of the DeepSeeker R1 model into its exclusive medical artificial intelligence (AI) product, CloudrBrain. The move aims to enhance CloudrBrain’s digital mining capabilities and improve the efficiency of chronic disease management through its hospital SaaS and pharmacy SaaS solutions. Enhancing AI-Driven…
-
Henlius’ Serplulimab Receives EU Approval for Extensive-Stage Small Cell Lung Cancer
•
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced that it has received marketing approval from the European Commission (EC) for its serplulimab, combined with carboplatin and etoposide, as a first-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) under the trade name Hetronifly. This approval marks serplulimab…
